Figure 2From: Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece Probability of rivaroxaban being cost effective at alternative willingness to pay thresholds: Acceptability Cost Effectiveness Curve. Back to article page